Apex Healthcare Berhad

 
  DOWNLOAD ANNUAL REPORT
  FINANCIAL RESULTS
 

XEPA


Xepa-Soul Pattinson

We develop, manufacture and market XEPA branded
off-patent generic pharmaceutical and medical devices
.

Founded in 1967 in Singapore, Xepa has grown and evolved at the cutting edge of the industry. From our modest first years when Xepa Laboratories Pte Ltd produced a limited range of pharmaceutical products in a small flatted factory, we have relocated twice to larger manufacturing plants in Melaka, Malaysia. Today, Xepa is a leading manufacturer of off-patent pharmaceuticals in Malaysia.

Xepa's research and development teams formulate new products which are then manufactured to exacting standards. Xepa’s in house sales and marketing team brands, positions, promotes and handles sales of the entire range of XEPA branded products to private and public sector medical clinics, polyclinics, pharmacies and hospitals, within Malaysia and the region.

Xepa's plant is at a 10-acre site in Cheng Industrial Estate in Melaka and comprises 39,484 square metres of development laboratories, production floors, warehouses and offices.

The Xepa range of products include cough mixtures and antihistamines, anti-infectives, anti-diabetics, anti-hypertensives, neuromuscular agents, analgesics, dermatologicals and ophthalmologicals in the form of tablets, capsules, oral liquid and suspension, creams and sterile eyedrops. The top-selling products include Bena and Sedilix, which are market leaders in the cough and cold category.

Xepa employs world-class (PIC/S) Good Manufacturing Practice. Its plant is ISO 9001:2015 certified for its Quality Management System and the laboratory is ISO/IEC 17025 certified. It is also certified for ISO 13485 that represents the requirements for a comprehensive quality management system for the design and manufacture of medical devices.

In September 2017, Xepa was awarded a Certificate Of GMP Compliance Of A Manufacturer (also known as EU GMP Certificate) by the national competent authority of Hungary on behalf of the European Medicines Agency. The scope of the certification encompasses a wide spectrum of manufacturing operations of human medicinal products, namely sterile (eye drops) and non-sterile products (solids, semi-solids and liquids), packaging (both primary and secondary) and quality control testing (microbiological and chemical/physical). This EU GMP certification is a key milestone in Xepa's strategy for sustainable long-term growth.

Over the next few years, Xepa will continuously embark on upgrading and expansion of its plant and facilities, which will keep it in the forefront of the regional market for years to come. Its new Oral Solid Dosage manufacturing facility (SPP NOVO) located at Cheng Industrial Estate Melaka is a vital infrastructure towards this end.

For further information, please visit www.xepasp.com

Xepa

Avex

Avo

AGNESIA

AVO DIAGNOSTICS

AGNESIA

AGNESIA

AGNESIA

AGNESIA

AGNESIA

AGNESIA

For further information, please visit www.xepasp.com/products/

Xepa's plant is at a 10-acre site in Cheng Industrial Estate in Melaka and comprises 39,484 square metres of development laboratories, production floors, warehouses and offices.

Apex office Vietnam
SPP NOVO, Xepa's new Oral Solid Dosage manufacturing plant located at Cheng Industrial Estate Melaka.